down-regulates IL-6 and other proin¯ammatory cytokines through the transcription factor nuclear factor kappa B (NFkB) [5] . Persistently elevated IL-10 release leads to postoperative monocyte dysfunction, termed immune paralysis, which may predispose to subsequent sepsis. 6 It is thought that Th1-rather than Th2-type responses may promote recovery, and indeed therapeutic strategies involving administration of the Th1 cytokine interferon g (IFN-g) are bene®cial. 7 Diclofenac is a cyclo-oxygenase inhibitor, which decreases prostaglandin release and hence the cAMP concentration, but the effects of diclofenac on IL-6 and IL-10 are not known. We hypothesized that diclofenac treatment during major surgery would alter IL-6 and IL-10 release and bene®cially modulate the in¯ammatory response. We therefore undertook a randomized controlled trial of perioperative diclofenac administration during major urological surgery.
Patients and methods
After ethical committee approval and written informed consent, patients scheduled for major urological surgery at the Alexandria Main University Hospital, Egypt, were included in a prospective randomized, double-blind, placebo-controlled trial. Patients with known sensitivity to non-steroidal anti-in¯ammatory drugs (NSAIDs) and those with a history of peptic ulceration or renal, cardiac, endocrine and/or haematological abnormalities were excluded. Patients who had received NSAIDs within 14 days before enrolment were also excluded. Consecutive patients scheduled for surgery within a prede®ned period of 1 yr were screened for suitability for enrolment. Randomization was performed using computer-generated random numbers. In the study group, 24 patients were randomized to receive perioperative diclofenac as 50 mg tablets every 8 h the day before surgery and 75 mg i.m. every 12 h on the day of surgery. Twenty-four patients were randomized to receive identical placebo tablets and i.m. saline at the same dosing intervals. All patients received oral ranitidine 300 mg on the day before surgery and 50 mg i.m. 8-hourly on the day of surgery. All staff were unaware of which patients received diclofenac or placebo.
All patients received a standardized anaesthetic technique comprising premedication with 10±20 mg oral diazepam 2 h before surgery and a combined general/epidural technique. Patients were¯uid-loaded with hydroxyethyl starch 12±14 ml kg ±1 and an epidural catheter was sited at L2±3. A test dose of 0.5% bupivacaine 3 ml alone was then given, followed by 4 ml increments of 0.25% bupivacaine with fentanyl 5 mg ml ±1 to produce bilateral loss of sensation to pinprick and cold from S5 to T4. The block was maintained with 0.25% bupivacaine and fentanyl 5 mg ml ±1 at 5±10 ml h ±1 throughout the surgical procedure. General anaesthesia was induced with thiopental 4±7 mg kg ±1 and fentanyl 2 mg kg ±1 and patients also received pancuronium 0.08±0.1 mg kg ±1 . Patients were ventilated to maintain normocapnia, and anaesthesia was maintained with 0.5±1% iso¯urane and 60% nitrous oxide in oxygen. Central venous catheters were inserted routinely before surgery. At the end of surgery, neuromuscular blockade was reversed with neostigmine 40 mg kg ±1 and glycopyrrolate 10 mg kg ±1 . Central venous pressure was maintained at 8±12 cm H 2 O and blood transfusion was only given if blood loss exceeded 20% of the empirically estimated blood volume (75 ml kg ±1 body weight). In the recovery area, the level of sensory block was reassessed and increments of 0.125% bupivacaine mixed with fentanyl 2 mg ml ±1 were given if required, to achieve optimal sensory blockade and control of pain.
After ful®lling the usual criteria for discharge, patients were transferred to a postanaesthetic care unit, where pain was controlled with epidural bupivacaine/fentanyl. The total volume used, the level of sensory block, and the degree of motor power were assessed hourly. Respiratory rate, tympanic temperature, mean arterial pressure and heart rate were recorded and pain intensity was assessed using a visual analogue scale 1 h after discharge, every 2 h for 4 h and every 4 h thereafter. The level of sedation was also assessed using a four-point scale on which 1 indicated awake, 2 easily arousable, 3 dif®cult to arouse and 4 unarousable. The anaesthetist in charge was called immediately if the sedation score was 3 or 4, if the respiratory rate was less than 10 b.p.m. or if there was any degree of motor loss in the lower extremities. Failure to institute and/or maintain adequate epidural analgesia constituted an exclusion criterion. Urine output was measured every 2 h and if oliguria of <0.5 ml kg ±1 h ±1 developed, furosemide 20 mg was given i.v. If oliguria persisted in spite of adequate central venous pressure, diclofenac/placebo was stopped and the patient was excluded from the study. The decision for this latter exclusion is based on the ethical consideration of not exposing these patients to further renal insult.
Blood samples were collected at 08.00 h on the day of surgery, and 30 min and 2, 6, 12, and 24 h after skin incision for IL-6 and IL-10 and cortisol measurement. Blood was centrifuged and serum stored at ±20°C until assay. Cytokines were measured using an in-house enzyme-linked immunosorbent assay using optimized reagents and antibody pairs and human recombinant IL-6/IL-10 as calibration standards (OptEIA; Pharmingen, San Diego, CA, USA). The detection limits for IL-6 and IL-10 were 4.7 and 7.8 pg ml ±1 respectively, and between-assay precision was consistently below 10% coef®cient of variation. Cortisol was measured using an enzyme immunoassay (Diagnostic Systems Laboratories, Webster, Texas, USA). The detection limit was 0.1 mg dl ±1 and precision was a coef®cient of variation <12%.
Blood samples were also collected at 08.00 h on the day of surgery and 24 h after skin incision for total leucocyte count and C-reactive protein determination. The C-reactive protein concentration was measured with the latex agglu-tination slide test (Randox Laboratories, Crumlin, UK) and the minimum detection level was 6 mg dl ±1 .
Statistical analysis
A power calculation was performed on the basis of an expected difference of 20% in IL-6 values between patient groups, at a power of 80%, P<0.05 (standard deviation 220 pg ml ±1 , based on previous studies). This indicated that 24 patients per group would be required. Normally distributed data are presented as mean (SD) and were analysed using Student's t-test and two-way analysis of variance as appropriate. Non-parametric data are presented as median (range) and were analysed with the Mann±Whitney U-test, Friedman analysis of variance and the Wilcoxon signed ranks test as appropriate. Correlations were assessed using the Spearman rank test and P<0.05 was taken as statistically signi®cant. Correction for multiple comparisons was undertaken whenever appropriate using the Bonferroni method.
Results
Patient groups were similar with respect to age, sex, blood loss, transfusion requirements, fentanyl consumption and type and duration of surgery (Table 1 ). All but three patients underwent surgery for malignancy. One patient was withdrawn from the control group because of surgical bleeding that necessitated reoperation, and one patient was withdrawn from the diclofenac group because of oliguria unresponsive to¯uid maximization and furosemide. In the latter case, adequate urine output was re-established within 48 h of exclusion from the study and did not require any further renal support interventions.
Circulating IL-6 concentrations increased during surgery and peaked at 12 h in both groups of patients (P<0.0001; Fig. 1 ). Post hoc testing showed that concentrations 2, 6, 12 and 24 h after skin incision were signi®cantly higher than baseline values in both diclofenac-and placebo-treated patients (P<0.001; Fig. 1 ). At 12 h, IL-6 concentrations were signi®cantly lower in the diclofenac group [385 (67±1291) pg ml ±1 ] compared with the placebo group [681 (201±1606) pg ml ±1 ; P=0.003; Fig. 1 ]. Peak IL-6 concentrations correlated with the duration of surgery in both groups (r S =0.76, P<0.0001 in the diclofenac group; r S =0.68, P=0.001 in the placebo group).
Circulating IL-10 concentrations also increased during surgery and peaked slightly earlier than IL-10, at 6 h, in both groups of patients (P<0.0001; Fig. 2 ). Post hoc testing showed that concentrations 2, 6, 12 and 24 h after skin incision were signi®cantly higher than baseline values in both diclofenac-and placebo-treated patients (P<0.001; Fig.  2 ). At 6 h, IL-10 concentrations were signi®cantly higher in the diclofenac-treated patients [136 (44±442) pg ml ±1 ] compared with the placebo group [84 (4±218) pg ml ±1 ; P=0.008; Fig. 2 ]. Peak IL-10 concentrations did not correlate with the duration of surgery in either group. Serum cortisol increased in both groups of patients (P<0.0001; Fig. 3 ) and was signi®cantly higher than baseline concentration at 30 min (P=0.01) and at 2, 6, 12 and 24 h (P<0.0001) in both groups (Fig. 3) . At 24 h, cortisol concentrations were lower in the diclofenac group than the placebo group [28 (10±42) mg dl ±1 and 36 (27±52) mg dl ±1 respectively; P=0.0018; Fig. 3 ] and correlated with peak IL-6 concentrations in the corresponding group (r S =0.76, P<0.0001 and r S =0.6, P<0.005, in the diclofenacand placebo-treated patients respectively).
Total leucocyte count, C-reactive protein concentration and body temperature were signi®cantly lower in diclofenac-treated patients compared with the placebo group at 24 h (P=0.0002, P=0.004 and P=0.03 respectively; Table 2 ). In both the diclofenac and the placebo group, C-reactive protein concentration at 24 h correlated with IL-6 concentration (r=0.85, P<0.0001 and r=0.82, P<0.0001, respectively). Pain scores, mean arterial pressure and heart rate were similar in the two groups throughout the study (Table 3) .
Discussion
We have shown increases in circulating IL-6 and IL-10 concentrations during and after major surgery, which were signi®cantly altered by diclofenac treatment. Peak concentrations of IL-6 were signi®cantly attenuated by diclofenac, whilst peak IL-10 concentrations were found to be higher. Other measures of the in¯ammatory response (cortisol, leucocyte count, C-reactive protein and temperature) were also lower in patients treated with diclofenac.
IL-6 concentrations increased in all patients during major surgery and correlated with the duration of the surgical procedure, as reported previously [8] . Cruickshank and colleagues 9 reported a similar correlation, although the extent of tissue trauma rather than the duration of surgery was thought to be the primary determinant of the IL-6 response. All but three of the patients in our study underwent surgery for malignancy. Although increased concentrations of both IL-6 and IL-10 have been reported to correlate with cancer staging, 10 11 we found no evidence of a pre-existing IL-10-mediated in¯ammatory response, as baseline concentrations of both cytokines were within ranges reported for healthy subjects. 10 11 Others have reported that IL-6 concentrations increase during surgery independently of the presence of cancer and again suggest that the extent of trauma and the duration of surgery are more important. 12 Although speci®c anaesthetic agents may affect cytokine release, there is little evidence for clinically relevant modulation of the in¯ammatory response by anaesthesia. Cytokine release during surgery is also related to the magnitude of the neuroendocrine stress response. Smaller increases in cortisol in conjunction with abrogated IL-6 release have been reported in patients undergoing general anaesthesia with large doses of opioids, 13 and other immune functions are also affected. However, combined epidural/ general anaesthesia, as used in the present study, did not result in reduced IL-6 concentrations compared with general anaesthesia alone.
14 In our study, IL-6 concentrations increased in all patients during surgery, but peak concentrations were signi®cantly lower in patients who received diclofenac treatment and were associated with decreased cortisol concentrations 12 h later. Similar reductions in IL-6 concentrations were found in patients undergoing cholecystectomy who were treated with ibuprofen. 15 IL-6 is known to stimulate ACTH and cortisol release, 16 and glucocorticoids inhibit IL-6 release. 17 However, cortisol concentrations increase earlier than circulating concentrations of IL-6; this increase is blocked during regional anaesthesia without affecting IL-6, 14 suggesting that IL-6 does not initiate the cortisol response to surgery. In our study, decreased IL-6 in diclofenac-treated patients preceded changes in cortisol in this group, suggesting that diclofe- In vitro studies using ®broblasts have shown that release of IL-6 is preceded by increases in cAMP. 18 Prostaglandins are known to increase intracellular concentrations of cAMP, 12±14 and NSAIDs such as diclofenac are potent inhibitors of IL-6 expression in several human cell lines. 19 Decreased IL-6 release in the present study may therefore have been mediated by reduced prostaglandin production and decreases in cAMP. 4 However, other mechanisms should also be considered. The transcription factor NFkB exists in cytoplasm in an inhibited state by virtue of the formation of a complex with the inhibitory subunit, IkB. The NSAID tepoxalin has been shown to inhibit IL-6 release from astrocytes through decreased NFkB activation as a result of stabilising the IkB, 20 in a similar manner to IL-10, 5 and diclofenac may therefore inhibit the release of IL-6 at the transcriptional level.
Interleukin-10 concentrations increased in this study during major surgery, as described previously, 6 and peaked slightly earlier than IL-6, at 6 rather than 12 h. This earlier peak is perhaps surprising as it might be expected that IL-6 release would precede that of IL-10.
1 Early IL-10 release has been described in patients undergoing other major surgery, such as coronary artery bypass grafting. 21 Our study certainly suggests that IL-10 release occurs before IL-6 and we also showed that diclofenac treatment increased IL-10 release. This is unexpected, as in vitro prostaglandins prime T cells for production of IL-10, and the regulation of cytokine balance in lymphocytes and macrophages depends on cyclo-oxygenase-2 activity for the up-regulation of IL-10 and down-regulation of IL-12 production. 22 However, studies using murine peritoneal macrophages showed that several NSAIDs increased IL-10 production, 23 and indometacin administration before experimental sepsis in rats was also associated with increased IL-10 production. 24 In addition, another in vitro study showed that prostaglandin E 1 suppressed IL-10 production by lipopolysaccharidestimulated mononuclear cells, 25 and certainly, because IL-10 is an anti-in¯ammatory agent, it might be expected that prostaglandins would decrease its release and the inhibition of prostaglandins would be associated with increased IL-10.
As peak concentrations of IL-6 occurred later than those of IL-10, it is possible that diclofenac treatment increased IL-10 production, which in turn down-regulated IL-6, in addition to any direct effects of cyclo-oxygenase inhibition on IL-6 via either cAMP or NFkB. IL-10 has consistently been shown to regulate proin¯ammatory cytokines, including IL-6, at the transcriptional level. The mechanism for the effect can be attributed either to IL-10-mediated decreased prostaglandin E 2 formation 26 or to IL-10-mediated stabilization of IkB. 6 NFkB is one of several transcription factors involved in the regulation of IL-6, 27 but the effects of IL-10 and diclofenac on other transcription factors, such as nuclear factor-IL-6, are not known. The differential effect of diclofenac on IL-6 and IL-10 during major surgery may be mediated through a combination of several mechanisms.
The attenuated rise in body temperature observed in the diclofenac group can be attributed simply to the antipyretic effect of the non-steroidal anti-in¯ammatory agent, as reported previously. 28 This effect is thought to be mediated through inhibition of prostaglandins and IL-6, both of which are endogenous pyrogens. Other anti-in¯ammatory effects of diclofenac were also observed in the present study, namely decreased leucocytosis and a smaller increase in Creactive protein. IL-6 up-regulates the release of acute phase proteins, including C-reactive protein, 29 and the effect of diclofenac may be mediated by IL-6. The low pain scores and the similarity of scores in the two groups of patients probably re¯ect the fact that the epidural was highly effective, as we intended, leaving little scope for the analgesic action of diclofenac. This indicates that our ®ndings are unrelated to differences in pain-induced stress responses between the groups, and it is clearly crucial.
In summary, we have shown that diclofenac administration during major surgery has differential effects on IL-6 and IL-10 release which may affect the in¯ammatory response. The concentration ratio of circulating IL-6 to IL-10 29 and the IL-10 concentration alone 6 have been shown to correlate with injury severity score in patients after trauma. Table 3 Mean arterial pressure, heart rate, pain scores and temperature in the two groups of patients before and after surgery. *Within-group differences (ANOVA). MAP=mean arterial pressure; NA=not applicable Before surgery Time after discharge from recovery area (h) P* Higher IL-10 concentrations are also associated with subsequent development of sepsis, 8 9 possibly because of the host's diminished antimicrobial defences. However, our ®ndings support the concept that altering the balance between IL-6 and IL-10 by treatment with diclofenac may be bene®cial, and this is suggested by the observed effects on leucocyte count, pyrexia and the acute phase response. Clearly, further large trials are required to determine the effects of this simple therapeutic strategy on morbidity and mortality.
